Loading...
XNAS
CELZ
Market cap2mUSD
Jul 09, Last price  
0.94USD
1D
-5.87%
1Q
-56.01%
IPO
-99.99%
Name

Creative Medical Technology Holdings Inc

Chart & Performance

D1W1MN
XNAS:CELZ chart
P/E
P/S
404.86
EPS
Div Yield, %
Shrs. gr., 5y
110.29%
Rev. gr., 5y
-48.43%
Revenues
6k
-45.45%
000000000004,800124,400165,500164,50087,75488,6009,00011,0006,000
Net income
-6m
L+9.13%
1,372-9,544-52,636-31,610-17,256-24,055-25,585-27,282-28,012-30,761-766,072-2,659,108-13,655,653-8,483,673-36,325,23019,211,768-10,144,044-5,286,574-5,493,481-5,995,008
CFO
-6m
L+10.47%
1,139-12,857-57,164-30,742-13,661-13,959-16,774-22,907-17,320-14,638-445,232-889,621-1,052,270-1,213,093-434,556-2,215,782-7,796,966-8,027,885-5,301,292-5,856,445

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
IPO date
May 01, 2009
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT